Latest Market News

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Andromeda Metals' latest Scoping Study reveals a compelling economic case for its innovative High Purity Alumina (HPA) production technology, highlighting strong returns and a significant carbon emissions advantage. The project aims to meet soaring global demand with a 10,000 tonne per annum facility in South Australia.

Resolution Minerals Ltd has successfully raised $25.1 million through a heavily supported placement, positioning itself to advance its Horse Heaven Project in Idaho and prepare for a NASDAQ listing.

Blue Star Helium Limited reports steady progress on its Galactica helium project in Colorado, with first helium production on track for December 2025 and full ramp-up expected through 2026.

Blue Star Helium has decided not to exercise its purchase option on key Colorado helium assets after thorough evaluation, signaling a strategic pivot in its growth approach.

Midas Minerals has raised $11.5 million through a strongly supported placement to fund its acquisition and exploration efforts at the Otavi Copper Project in Namibia.

Auravelle Resources reports standout high-grade gold results from its South Australian projects and outlines a robust exploration agenda targeting major gold deposits nearby.

Western Gold Resources Limited has had its trading suspension lifted following the release of initial assay results from its Duke Gold project and a response to an ASX price and volume query.

Western Gold Resources has responded to ASX inquiries about recent unusual trading activity, disclosing partial assay results from its Gold Duke drilling program while affirming compliance with continuous disclosure rules.

Highfield Resources has requested a voluntary suspension of its shares on the ASX to complete a capital raising, with trading expected to resume by 23 September 2025.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.